Neurogene vs Cartesian Therapeutics
NGNE and RNAC side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How NGNE and RNAC compare
Neurogene is the larger company, worth 2.4 times as much as Cartesian Therapeutics ($466M against $192M).
Neurogene scores higher on the StockData Score (6 against 1 for Cartesian Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | NGNE | RNAC |
|---|---|---|
| Size and price | ||
| Market cap | $466M | $192M |
| Share price | $23.30 | $6.35 |
| Change, 1 year | −12.0% | −16.2% |
| Change, 5 years | −77.2% | −93.4% |
| Beta (5Y) | 2.00 | – |
| Employees | 131 | 75 |
| StockData Score | ||
| Total score | 6 (better) | 1 |
| Valuation score | 0 | 0 |
| Growth score | 0 | 0 |
| Performance score | 1 (better) | 0 |
| Health score | 5 (better) | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | – | 130× |
| P/B | 2.1× | – |
| FCF yield | −18.8% (better) | −40.9% |
| Growth | ||
| Revenue growth, 5Y average | – | −30.0% |
| Profitability | ||
| Operating margin | – | −10519% |
| Net margin | – | −10284% |
| FCF margin | – | −5322% |
| Return on equity | −45.3% | – |
| Financial health | ||
| Debt / equity | 0.00 | – |
| Interest coverage | −60673.0× | – |
| Current ratio | 10.64 (better) | 7.48 |
| Altman Z-score | 7.26 (better) | −4.56 |
| Piotroski F-score | 2 | 2 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 86.5% | 29.3% |
| Held by insiders | 15.9% | 55.7% |
| Insider net buying, 12 months | −$1.1M | −$52.9K (better) |
| Short interest, % of float | 33.8% | 14.3% |
Go deeper
- NGNE stock overview
- NGNE income statement
- NGNE valuation and score
- RNAC stock overview
- RNAC income statement
- RNAC valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.